![CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML](https://www.mdpi.com/cimb/cimb-44-00059/article_deploy/html/images/cimb-44-00059-g002.png)
CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML
![Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine - Virtual Meeting | EASD Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine - Virtual Meeting | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/287678/Slide1.jpg)
Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine - Virtual Meeting | EASD
![Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes – topic of research paper in Medical engineering. Download scholarly article PDF Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes – topic of research paper in Medical engineering. Download scholarly article PDF](https://cyberleninka.org/viewer_images/659761/f/1.png)
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes – topic of research paper in Medical engineering. Download scholarly article PDF
![PDF) Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase PDF) Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase](https://i1.rgstatic.net/publication/50374909_Insulin_degludec_an_ultra-long-acting_basal_insulin_once_a_day_or_three_times_a_week_versus_insulin_glargine_once_a_day_in_patients_with_type_2_diabetes_A_16-week_randomised_open-label_phase_2_trial/links/5d2cf61b299bf1547cb9cf76/largepreview.png)
PDF) Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase
![Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2001013503/2003813987/gr1.gif)
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2
![PDF) Insulin degludec: A novel ultra-acting basal insulin: Potential usefulness in hospitalized patients PDF) Insulin degludec: A novel ultra-acting basal insulin: Potential usefulness in hospitalized patients](https://i1.rgstatic.net/publication/299404568_Insulin_degludec_A_novel_ultra-acting_basal_insulin_Potential_usefulness_in_hospitalized_patients/links/57ebd2ac08aebb1961ff8cb7/largepreview.png)
PDF) Insulin degludec: A novel ultra-acting basal insulin: Potential usefulness in hospitalized patients
![28/01/2019. Werking kinderdiabetesteam Brugge. Hoe verloopt de normale insulinesecretie. De behandeling van diabetes type 1. - PDF Gratis download 28/01/2019. Werking kinderdiabetesteam Brugge. Hoe verloopt de normale insulinesecretie. De behandeling van diabetes type 1. - PDF Gratis download](http://docplayer.nl/docs-images/100/148014259/images/9-6.jpg)
28/01/2019. Werking kinderdiabetesteam Brugge. Hoe verloopt de normale insulinesecretie. De behandeling van diabetes type 1. - PDF Gratis download
![Frontiers | Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales | Pharmacology Frontiers | Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales | Pharmacology](https://www.frontiersin.org/files/Articles/807548/fphar-12-807548-HTML/image_m/fphar-12-807548-g001.jpg)
Frontiers | Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales | Pharmacology
![CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML](https://www.mdpi.com/cimb/cimb-44-00059/article_deploy/html/images/cimb-44-00059-g007.png)
CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML
![Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function | Cardiovascular Diabetology | Full Text Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function | Cardiovascular Diabetology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-016-0410-9/MediaObjects/12933_2016_410_Fig1_HTML.gif)
Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function | Cardiovascular Diabetology | Full Text
![In the solvent conditions in insulin degludec formulation, the presence... | Download Scientific Diagram In the solvent conditions in insulin degludec formulation, the presence... | Download Scientific Diagram](https://www.researchgate.net/profile/Marcos-Tambascia/publication/279728896/figure/fig2/AS:267628400869381@1440818991058/In-the-solvent-conditions-in-insulin-degludec-formulation-the-presence-of-zinc-and_Q640.jpg)
In the solvent conditions in insulin degludec formulation, the presence... | Download Scientific Diagram
![Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial - Rodbard - 2013 - Diabetic Medicine - Wiley Online Library Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial - Rodbard - 2013 - Diabetic Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c53f588e-58c2-49e7-8a7e-c5f79645ea21/dme.2013.30.issue-11.cover.jpg)
Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial - Rodbard - 2013 - Diabetic Medicine - Wiley Online Library
![A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance | SpringerLink A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40262-014-0165-y/MediaObjects/40262_2014_165_Fig1_HTML.gif)
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance | SpringerLink
![CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML CIMB | Free Full-Text | Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons | HTML](https://www.mdpi.com/cimb/cimb-44-00059/article_deploy/html/images/cimb-44-00059-g005-550.jpg)